Stock STOK STOKE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Stoke Therapeutics, Inc.

Equities

STOK

US86150R1077

Real-time Estimate Cboe BZX
Other stock markets
 11:54:57 2024-06-10 am EDT 		5-day change 1st Jan Change
15.08 USD +1.51% Intraday chart for Stoke Therapeutics, Inc. -2.62% +186.60%
May. 27 Certain Pre-Funded Warrants of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI
May. 27 Certain Common Stock of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024. CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
BU
Certain Pre-Funded Warrants of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
CI
Certain Common Stock of Stoke Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 27-MAY-2024.
CI
Stoke Therapeutics Insider Sold Shares Worth $653,529, According to a Recent SEC Filing
MT
Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
BU
Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating
MT
Stoke Therapeutics : Corporate Presentation - May 2024
PU
Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M
MT
Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates
BU
Stoke Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Stoke Therapeutics Appoints Thomas Leggett CFO
MT
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
BU
Stoke Therapeutics, Inc. Announces Executive Changes, Effective May 7, 2024
CI
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
BU
Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer
CI
Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
BU
Sector Update: Health Care Stocks Advance Premarket Thursday
MT
Stoke Therapeutics Prices Upsized $125 Million Share Offering
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. STOK Stock
  4. News Stoke Therapeutics, Inc.